Recent interims confirmed the growth outlook is on track. Whilst the revenue model is changing, our profit forecasts are unchanged (3yr EPS CAGR of 15%). We await potential positive catalysts in the form of the lifting of the restriction on Cardioxane and further product acquisitions. The recent pull back looks like a good entry opportunity. We stay at Buy with an unchanged 895p Target Price.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Clinigen Group - Recent weakness another opportunity
- Published:
13 Apr 2017 -
Author:
Chris Glasper -
Pages:
5
Recent interims confirmed the growth outlook is on track. Whilst the revenue model is changing, our profit forecasts are unchanged (3yr EPS CAGR of 15%). We await potential positive catalysts in the form of the lifting of the restriction on Cardioxane and further product acquisitions. The recent pull back looks like a good entry opportunity. We stay at Buy with an unchanged 895p Target Price.